The estimated Net Worth of James M Daly is at least $9.35 Milion dollars as of 29 May 2024. Mr. Daly owns over 6,652 units of Madrigal Pharmaceuticals Inc stock worth over $5,744,382 and over the last 12 years he sold MDGL stock worth over $2,293,262. In addition, he makes $1,309,500 as Independent Director at Madrigal Pharmaceuticals Inc.
James has made over 26 trades of the Madrigal Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 6,652 units of MDGL stock worth $1,549,916 on 29 May 2024.
The largest trade he's ever made was exercising 158,331 units of Madrigal Pharmaceuticals Inc stock on 13 February 2014 worth over $2,688,460. On average, James trades about 9,010 units every 52 days since 2012. As of 29 May 2024 he still owns at least 24,654 units of Madrigal Pharmaceuticals Inc stock.
You can see the complete history of Mr. Daly stock trades at the bottom of the page.
James M. Daly is Independent Director of the Company. n June 27, 2019, our Board of Directors appointed James M. Daly as a member of our Board of Directors. Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and also currently serves as a Director of Acadia Pharmaceuticals, argenx SE, Bellicum Pharmaceuticals, and Halozyme Therapeutics. He previously served on the board of directors of Chimerix, Inc. Most recently, Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015. Previously, Mr. Daly worked for Amgen, Inc. and held various leadership positions over a 10-year period, including his last role as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Earlier in his career, he spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK), where he held roles of increasing responsibility, including his last role as Senior Vice President, General Manager of the Respiratory and Anti-Infective Business Unit. He earned a B.S. in Pharmacy and an M.B.A. from the University at Buffalo, The State University of New York.
As the Independent Director of Madrigal Pharmaceuticals Inc, the total compensation of James Daly at Madrigal Pharmaceuticals Inc is $1,309,500. There are 4 executives at Madrigal Pharmaceuticals Inc getting paid more, with Paul Friedman having the highest compensation of $6,093,190.
James Daly is 58, he's been the Independent Director of Madrigal Pharmaceuticals Inc since 2019. There are 11 older and 5 younger executives at Madrigal Pharmaceuticals Inc. The oldest executive at Madrigal Pharmaceuticals Inc is David Milligan, 79, who is the Independent Director.
James's mailing address filed with the SEC is C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, 19428.
Over the last 8 years, insiders at Madrigal Pharmaceuticals Inc have traded over $471,222,585 worth of Madrigal Pharmaceuticals Inc stock and bought 443,785 units worth $79,114,183 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Paul A Friedman a Bros. Advisors Lp667, L.P.B.... On average, Madrigal Pharmaceuticals Inc executives and independent directors trade stock every 56 days with the average trade being worth of $20,602,093. The most recent stock trade was executed by William John Sibold on 9 September 2024, trading 6,363 units of MDGL stock currently worth $1,551,490.
madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.
Madrigal Pharmaceuticals Inc executives and other stock owners filed with the SEC include: